Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome – Biogen

1. Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome  Biogen
2. Beyond Seizures: Zorevunersen’s Impact on Cognition and Function  NeurologyLive
3. Biogen & Stoke: Zorevunersen Shows 95% Clinical Improvement at 3 Years | BIIB Stock News  Stock Titan
4. Overviewing Early-Stage Efficacy, Safety Data of Zorevunersen  NeurologyLive
5. Zorevunersen and the Next Chapter of Dravet Syndrome Care  NeurologyLive

Continue Reading